康希诺生物(6185.HK)盘中拉升涨超8%，报53港元。公司8月20日晚公布业绩显示，2025年上半年实现营收3.74亿元，同比增长31.1%；归属于上市公司股东的净亏损1348.5万元，上年同期净亏损2.25亿元，同比大幅减亏。 美银证券发表报告指，康希诺上半年营收同比增长31.1%，净亏损收窄。由于MCV4 Menhycia的销售增长，上半年来自脑膜炎球菌疫苗的收入同比增长38.4%。受惠于高利润疫苗销售额上升及产能利用率提升，上半年疫苗产品的毛利率提升至79.3%，同比上升12个百分点。美银证券上调2028年至2034年每股盈利预测7%-11%，考虑到其在多种技术路线的领先研发能力及强劲的海外扩张能力，重申对康希诺生物“买入”评级，目标价由43港元升至56港元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.